ArticleTobacco induced diseases2025
Cannabis products and trends in a cohort of young adults: The VapeScan longitudinal study.
Article in Tobacco induced diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionCannabis is the third most used drug in the world with emerging legalization in the US and other countries. In a descriptive analysis, we report trends in cannabis use and types of products used in the VapeScan longitudinal study, a cohort study of young adults designed to investigate subclinical health effects of e-cigarette use.
methodsThe VapeScan study recruited 372 adults aged 18-50 years in the New York City area in 2021-2024, independently of cannabis use. At Visit 1, we asked about cannabis use, and at Visit 2, we implemented a more detailed questionnaire to characterize longitudinal trends and methods of cannabis use. We performed descriptive analyses to compare and report cannabis and tobacco use among participants groups of: 1) no substance use, 2) exclusive cannabis use, 3) exclusive e-cigarette use, and 4) dual substance use (e-cigarette and cannabis use).
resultsParticipants had a median age of 26 years (IQR: 21-33), were 50.5% male, 48.1% female, and 1.3% non-binary. At Visit 1, 125 (33.6%) participants reported dual substance use, 15 (4%) reported exclusive cannabis use, 129 (34.7%) reported e-cigarette but no cannabis use, and 103 (27.7%) reported no substance use. At Visit 2, 128 of 217 (58.9%) participants reported cannabis use; 63 (29.0%) vape cannabis, 61 (28.1%) smoke cannabis, 111 (51.2%) edible cannabis, 69 (31.8%) CBD, and 8 (3.7%) topical cannabis. Frequency and intensity varied by method of use. Self-reported trends of vaped or smoked cannabis use varied between visits, with 28 (20.9%) becoming new users at Visit 2, while quitting only happened in 5 (6.3%) of those who vaped or smoked cannabis at Visit 1 (p=0.007).
conclusionsOur findings support that cannabis use is diverse and complex and is growing in urban communities, requiring further investigation to better understand use patterns and potential exposure to cannabis-related contaminants and related health effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.